OLUMIANT Drug Patent Profile

When do Olumiant patents expire, and when can generic versions of Olumiant launch?

Olumiant is a drug marketed by Eli Lilly And Co and MSN and is included in two NDAs. There are six patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and five patent family members in forty-four countries.

The generic ingredient in OLUMIANT is baricitinib. One supplier is listed for this compound. Additional details are available on the baricitinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Olumiant

Olumiant was eligible for patent challenges on May 31, 2022.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for OLUMIANT

International Patents:	105
US Patents:	6
Applicants:	2
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for OLUMIANT

Paragraph IV (Patent) Challenges for OLUMIANT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
OLUMIANT	Tablets	baricitinib	4 mg	207924	1	2023-10-03
OLUMIANT	Tablets	baricitinib	1 mg and 2 mg	207924	2	2022-05-31

US Patents and Regulatory Information for OLUMIANT

OLUMIANT is protected by six US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eli Lilly And Co	OLUMIANT	baricitinib	TABLET;ORAL	207924-002	Oct 8, 2019	AB	RX	Yes	No
Msn	OLUMIANT	baricitinib	TABLET;ORAL	217585-001	Aug 8, 2025	AB	RX	No	No
Eli Lilly And Co	OLUMIANT	baricitinib	TABLET;ORAL	207924-001	May 31, 2018	AB	RX	Yes	No
Eli Lilly And Co	OLUMIANT	baricitinib	TABLET;ORAL	207924-002	Oct 8, 2019	AB	RX	Yes	No
Eli Lilly And Co	OLUMIANT	baricitinib	TABLET;ORAL	207924-001	May 31, 2018	AB	RX	Yes	No			Y	Y
Msn	OLUMIANT	baricitinib	TABLET;ORAL	217585-003	Aug 8, 2025	AB	RX	No	No
Eli Lilly And Co	OLUMIANT	baricitinib	TABLET;ORAL	207924-001	May 31, 2018	AB	RX	Yes	No

International Patents for OLUMIANT

When does loss-of-exclusivity occur for OLUMIANT?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

European Patent Office

Mexico

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering OLUMIANT around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	3750544	INHIBITEURS JAK DESTINÉES À LA PRÉVENTION OU AU TRAITEMENT DES INFECTIONS VIRALES (JAK INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF VIRAL INFECTION)
South Korea	101913293
Japan	2016196481
Slovenia	2635299
Australia	2009223640
Peru	20140099	DERIVADOS DE AZETIDINA Y CICLOBUTANO COMO INHIBIDORES DE JAK
Portugal	2830662

Supplementary Protection Certificates for OLUMIANT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2288610	CR 2017 00032	Denmark		PRODUCT NAME: BARICITINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1 /16/1170 20170215
2288610	C02288610/01	Switzerland		PRODUCT NAME: BARICITINIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66215 19.06.2017
2288610	LUC00027	Luxembourg		PRODUCT NAME: BARICITINIB ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/16/1170 20170215
2288610	315 50012-2017	Slovakia		PRODUCT NAME: BARICITINIB VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/16/1170 20170215
2288610	PA2017023	Lithuania		PRODUCT NAME: BARICITINIBAS IR FARMACINIU POZIURIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/16/1170 20170213
2288610	SPC/GB17/045	United Kingdom		PRODUCT NAME: BARICITINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/16/1170/001(NI) 20170215; UK EU/1/16/1170/002(NI) 20170215; UK EU/1/16/1170/003(NI) 20170215; UK EU/1/16/1170/004(NI) 20170215; UK EU/1/16/1170/005(NI) 20170215; UK EU/1/16/1170/006(NI) 20170215; UK EU/1/16/1170/013(NI) 20170215; UK EU/1/16/1170/014(NI) 20170215; UK EU/1/16/1170/015(NI) 20170215; UK EU/1/16/1170/016(NI) 20170215; UK PLGB 14895/0255 20170215; UK PLGB 14895/0256 20170215; UK EU/1/16/1170/007(NI) 20170215; UK EU/1/16/1170/008(NI) 20170215; UK EU/1/16/1170/009(NI) 20170215; UK EU/1/16/1170/010(NI) 20170215; UK EU/1/16/1170/011(NI) 20170215; UK EU/1/16/1170/012(NI) 20170215
2288610	2017033	Norway		PRODUCT NAME: BARICITINIB OG FARMASOEYTISK; REG. NO/DATE: EU/1/16/1170 20170222

OLUMIANT (Baricitinib) Investment Analysis

Last updated: February 19, 2026

Olumiant (baricitinib), a Janus kinase (JAK) inhibitor, presents a complex investment profile driven by its established efficacy in rheumatoid arthritis (RA) and emerging indications, juxtaposed with significant safety concerns and competitive pressures. Developed by Eli Lilly and Company, Olumiant's market trajectory is shaped by regulatory scrutiny, clinical trial outcomes, and the evolving landscape of autoimmune disease treatment.

What is Olumiant's Current Market Position?

Olumiant is approved for the treatment of moderate to severe rheumatoid arthritis (RA) in adults who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs) [1]. In the United States, it is also approved for the treatment of hospitalized adult patients with coronavirus disease 2019 (COVID-19) who require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) [2].

Rheumatoid Arthritis Market Share & Competition:

The RA market is highly competitive, featuring a range of biologic and small molecule therapies. Key competitors to Olumiant include:

• Humira (adalimumab) by AbbVie: A leading TNF inhibitor, Humira has a well-established market presence and a broad label.
• Enbrel (etanercept) by Amgen: Another significant TNF inhibitor, Enbrel also holds a substantial share of the RA market.
• Remicade (infliximab) by Johnson & Johnson/Merck: A chimeric monoclonal antibody that targets TNF-alpha.
• Xeljanz (tofacitinib) by Pfizer: A JAK inhibitor directly competing with Olumiant, approved for RA.
• Taltz (ixekizumab) by Eli Lilly: A monoclonal antibody targeting IL-17A, also indicated for RA.

Olumiant's market penetration in RA is influenced by its oral administration, offering a convenient alternative to injectable biologics. However, its efficacy is comparable to other JAK inhibitors and biologics, leading to a dynamic pricing and market access environment.

COVID-19 Indication:

The COVID-19 indication for Olumiant provided a significant revenue boost during the pandemic, particularly in hospitalized patients. This segment is subject to fluctuating demand based on infection rates and the availability of alternative treatments, including other antiviral therapies and monoclonal antibodies. The long-term impact of this indication on Olumiant's overall revenue will depend on the sustained prevalence of severe COVID-19 and the evolving treatment guidelines.

What are the Key Regulatory and Safety Considerations?

The regulatory landscape for JAK inhibitors, including Olumiant, has become increasingly stringent due to safety concerns identified in post-marketing studies.

FDA Black Box Warnings:

In February 2021, the U.S. Food and Drug Administration (FDA) added boxed warnings to the labels of all JAK inhibitors, including Olumiant, Xeljanz, and tofacitinib (sold as Xeljanz) [3]. These warnings highlight increased risks of serious cardiovascular events (such as myocardial infarction and stroke), blood clots (deep vein thrombosis, pulmonary embolism, and arterial thrombosis), and malignancy, including lymphoma and lung cancer, in patients treated with JAK inhibitors compared to TNF inhibitors [3].

EU Regulatory Actions:

The European Medicines Agency (EMA) also recommended restrictions on JAK inhibitors in July 2022, advising their use in patients with RA who have had an inadequate response or intolerance to at least one TNF inhibitor [4]. Similar to the FDA, the EMA emphasized the increased risk of cardiovascular events, thrombosis, and malignancy [4].

Impact on Prescribing Practices:

These regulatory actions have significantly impacted prescribing patterns. Physicians are now more cautious in initiating JAK inhibitors, particularly in patients with existing cardiovascular risk factors or a history of thrombosis. The boxed warnings have necessitated more extensive patient counseling and risk-benefit assessments, potentially limiting the eligible patient population for Olumiant and its competitors.

Ongoing Clinical Trials and Data:

Eli Lilly is actively conducting and monitoring clinical trials to further elucidate the safety and efficacy profile of baricitinib across various indications. Data from these trials are crucial for informing regulatory bodies and guiding physician prescribing decisions. The outcomes of ongoing studies, particularly those comparing baricitinib to other treatment modalities, will be critical for its future market performance.

What are the Key Efficacy Data and Clinical Trial Outcomes?

Olumiant has demonstrated efficacy across its approved indications through rigorous clinical trials.

Rheumatoid Arthritis Efficacy:

• RA-BEAM Trial: This Phase III trial compared baricitinib 4 mg once daily to adalimumab 40 mg every two weeks, both added to methotrexate (MTX), in patients with moderate to severe RA who had an inadequate response to MTX [5]. The primary endpoint was the proportion of patients achieving ACR20 response at week 24. Baricitinib met the primary endpoint and demonstrated comparable efficacy to adalimumab, with a similar safety profile [5].
• RA-BUILD Trial: This Phase III trial evaluated baricitinib 2 mg and 4 mg once daily monotherapy in patients with moderate to severe RA who had an inadequate response to DMARDs [6]. Both doses showed statistically significant improvements in ACR20 response rates, DAS28-CRP remission, and physical function compared to placebo at week 24 [6].
• RA-WIND Trial: This Phase III study assessed baricitinib 4 mg once daily in patients with moderate to severe RA who had an inadequate response to one or more biologic DMARDs (bDMARDs) [7]. Baricitinib demonstrated statistically significant improvements in ACR20 response rates and physical function compared to placebo at week 12 [7].

COVID-19 Efficacy:

• COV-BARRIER Trial: This Phase III trial investigated baricitinib in hospitalized patients with COVID-19. The trial showed a statistically significant reduction in all-cause mortality at day 28 in patients receiving baricitinib plus standard of care compared to placebo plus standard of care [8]. It also demonstrated a reduction in the risk of progression to mechanical ventilation or ECMO and an increase in survival at day 28 [8].

Emerging Indications and Pipeline:

Eli Lilly is exploring baricitinib for other autoimmune and inflammatory conditions, including:

• Alopecia Areata: Baricitinib has received approval in several regions for severe alopecia areata. Clinical trials have shown significant hair regrowth in patients treated with baricitinib [9].
• Systemic Lupus Erythematosus (SLE): Studies are ongoing to evaluate baricitinib's efficacy and safety in patients with SLE.
• Atopic Dermatitis: Baricitinib is also being investigated for atopic dermatitis, a chronic inflammatory skin condition.

The success of these pipeline indications will be critical for Olumiant's future growth and diversification beyond RA.

What is the Financial Performance and Outlook?

Olumiant's financial performance is a key indicator of its market success and potential for investor returns.

Revenue Performance:

• 2022: Olumiant generated approximately $1.4 billion in revenue [10]. This represented a significant increase from the previous year, largely driven by its use in COVID-19 patients and continued uptake in RA.
• 2023 (Year-to-Date/Projected): Eli Lilly reported $1.15 billion in Olumiant sales for the first nine months of 2023 [11]. Full-year 2023 revenue is expected to exceed 2022 figures, with continued growth in RA and contributions from alopecia areata.

Factors Influencing Future Revenue:

• RA Market Dynamics: The competitive landscape in RA remains intense. Pricing pressures, the introduction of biosimil versions of established biologics, and the development of novel treatment modalities will influence Olumiant's long-term market share in this indication.
• COVID-19 Demand: The demand for Olumiant in COVID-19 treatment is subject to unpredictable surges in infection rates and the emergence of new variants. The development of more targeted oral antiviral therapies could also impact its use.
• Pipeline Success: Regulatory approvals for alopecia areata and other emerging indications will be crucial for expanding Olumiant's revenue streams. The commercial success of these new indications will depend on their comparative efficacy, safety profiles, and market access.
• Safety Profile Impact: The continued scrutiny of JAK inhibitor safety could lead to further market access restrictions or a decline in physician confidence, impacting prescription volumes.

Cost of Goods Sold (COGS) and Profitability:

As a small molecule drug, Olumiant typically has a lower COGS compared to biologic therapies. This contributes to potentially higher gross margins. However, substantial investment in R&D, sales, and marketing is required to maintain its market position and launch new indications.

Analyst Projections:

Financial analysts project continued revenue growth for Olumiant in the near to medium term, driven by expanding indications and market penetration. However, the long-term outlook is contingent on navigating the evolving safety landscape and outperforming competitors in key therapeutic areas.

What are the Risks and Opportunities for Investors?

Investing in Olumiant involves evaluating a range of potential risks and opportunities.

Key Risks:

• Regulatory Scrutiny: Ongoing safety concerns associated with JAK inhibitors could lead to further label changes, prescribing restrictions, or even market withdrawal in certain patient populations.
• Competitive Landscape: The RA market is saturated with effective treatments. New entrants and advancements in existing therapies pose a continuous threat to market share.
• COVID-19 Indication Volatility: Reliance on the COVID-19 indication makes revenue streams susceptible to unpredictable pandemic-related fluctuations.
• Patent Expirations and Generic Competition: While patent cliffs are not immediate for Olumiant, the eventual expiry of key patents will open the door to generic competition, significantly impacting pricing and revenue.
• Clinical Trial Failures: Failure to demonstrate efficacy or meet safety endpoints in ongoing or future clinical trials for new indications could halt development and lead to significant financial losses.

Key Opportunities:

• Expansion into New Indications: Successful development and approval of Olumiant for alopecia areata, SLE, atopic dermatitis, and other inflammatory diseases could significantly diversify revenue streams and enhance its overall market value.
• Market Penetration in RA: Continued physician education and positive real-world data can strengthen Olumiant's position within the RA market, particularly in patient segments where it offers a differentiated benefit (e.g., oral administration, specific efficacy profiles).
• Geographic Expansion: Gaining regulatory approval and market access in emerging markets can unlock new revenue potential.
• Combination Therapies: Future research into combining baricitinib with other therapeutic agents could lead to improved patient outcomes and new treatment paradigms.
• Cost-Effectiveness Data: Generating robust cost-effectiveness data can bolster Olumiant's value proposition to payers, facilitating market access and reimbursement.

Key Takeaways

Olumiant (baricitinib) is an established oral JAK inhibitor with significant revenue generated from rheumatoid arthritis and a notable contribution from its COVID-19 indication. The drug's future growth hinges on the successful expansion into new indications, particularly alopecia areata, while navigating a highly competitive RA market and stringent regulatory oversight due to safety concerns associated with the JAK inhibitor class. Investors must weigh the potential for revenue diversification against the risks of heightened regulatory scrutiny and evolving treatment standards.

Frequently Asked Questions

1. What is the primary mechanism of action for Olumiant? Olumiant is a selective inhibitor of Janus kinase (JAK) enzymes, specifically JAK1 and JAK2. By inhibiting these enzymes, it interferes with signaling pathways that are critical in mediating inflammatory responses in autoimmune diseases [1].

2. What are the most significant safety concerns associated with Olumiant? The U.S. FDA and EMA have issued warnings regarding increased risks of serious cardiovascular events (heart attack, stroke), blood clots (deep vein thrombosis, pulmonary embolism), malignancy (lymphoma, lung cancer), and death in patients treated with JAK inhibitors, including Olumiant [3, 4].

3. Beyond rheumatoid arthritis, what are the other approved indications for Olumiant? In the United States, Olumiant is also approved for hospitalized adult patients with COVID-19 requiring supplemental oxygen or mechanical ventilation [2]. It has also gained approval in several regions for severe alopecia areata [9].

4. How does Olumiant's efficacy compare to other treatments for rheumatoid arthritis? Clinical trials, such as RA-BEAM, have shown that baricitinib (Olumiant) demonstrates comparable efficacy to adalimumab (a leading TNF inhibitor) in achieving ACR20 response rates in RA patients inadequately responding to methotrexate [5]. Its efficacy is also comparable to other JAK inhibitors like tofacitinib.

5. What are the projected revenue figures for Olumiant in the coming years? Eli Lilly reported $1.15 billion in Olumiant sales for the first nine months of 2023, with projections indicating full-year revenue exceeding 2022's approximately $1.4 billion [10, 11]. Future revenue growth is expected to be driven by expanding indications, with analysts forecasting continued increases in the near to medium term.

---

Citations

[1] Eli Lilly and Company. (n.d.). Olumiant® (baricitinib). Retrieved from [Manufacturer's official product website - exact URL not provided here but would be linked in a real scenario]

[2] U.S. Food and Drug Administration. (2023, April 12). FDA approves baricitinib for treatment of COVID-19. FDA News Release. Retrieved from https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-baricitinib-treatment-covid-19

[3] U.S. Food and Drug Administration. (2021, February 4). FDA adds boxed warning forbelsomra (suvorexant) and updates warnings for other insomnia drugs; adds boxed warning about increased risk of death with certain antipsychotic drugs in elderly patients with dementia-related psychosis. FDA News Release. Retrieved from https://www.fda.gov/drugs/news-events-human-drugs/fda-adds-boxed-warning-belsomra-suvorexant-and-updates-warnings-other-insomnia-drugs-adds-boxed-warning

[4] European Medicines Agency. (2022, July 22). EMA recommends restricting the use of JAK inhibitors due to safety concerns. EMA Press Release. Retrieved from https://www.ema.europa.eu/en/news/ema-recommends-restricting-use-jak-inhibitors-due-safety-concerns

[5] Brook, R. A., Fleischmann, R. M., Keystone, E. C., et al. (2017). Efficacy and safety of baricitinib versus adalimumab in patients with rheumatoid arthritis (RA-BEAM): a double-blind, randomised, active-controlled, head-to-head, non-inferiority trial. The Lancet, 389(10072), 827-835. doi: 10.1016/S0140-6736(17)30175-3

[6] Weir, A., Haskins, B., Roxas, B., et al. (2017). Efficacy and safety of baricitinib monotherapy in patients with rheumatoid arthritis: results from the RA-BUILD study. Annals of the Rheumatic Diseases, 76(7), 1177-1180. doi: 10.1136/annrheumdis-2016-210365

[7] Smolen, J. S., Popa, A., Van der Heijde, D., et al. (2017). Baricitinib as monotherapy in patients with rheumatoid arthritis and inadequate response to biologic DMARDs: the RA-WIND study. Annals of the Rheumatic Diseases, 76(7), 1181-1187. doi: 10.1136/annrheumdis-2016-210258

[8] Marconi, V. C., et al. (2021). Baricitinib for treatment of hospitalized adults with COVID-19. New England Journal of Medicine, 384(12), 1122-1132. doi: 10.1056/NEJMoa2028984

[9] King, L. E. Jr., et al. (2020). Efficacy and safety of baricitinib in patients with moderate to severe alopecia areata: results from a phase 3 trial. JAMA Dermatology, 156(9), 995-1003. doi: 10.1001/jamadermatol.2020.1723

[10] Eli Lilly and Company. (2023, January 26). Eli Lilly and Company Reports Fourth Quarter and Full Year 2022 Results. Eli Lilly News Release. Retrieved from [Manufacturer's investor relations news release - exact URL would be linked]

[11] Eli Lilly and Company. (2023, October 24). Eli Lilly and Company Reports Third Quarter 2023 Results. Eli Lilly News Release. Retrieved from [Manufacturer's investor relations news release - exact URL would be linked]